Medical Oncology Department, University Hospital La Paz, Madrid, Spain.
Urol Oncol. 2012 Jul-Aug;30(4):356-61. doi: 10.1016/j.urolonc.2009.11.008. Epub 2010 Mar 5.
Renal cell carcinoma therapy has changed in a very significant way in the last few years. Up to 5 new agents have been developed, improving the results previously achieved with cytokine therapy. Bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus are now part of the therapeutic arsenal for this illness. Particularly, this has been the first tumoral type in which inhibition of mammalian target of rapamycin (mTOR) has proved its efficacy in phase III trials, either as first-line therapy for poor prognosis patients (temsirolimus, CCI-779) or as second-line therapy after failure of tyrosine-kinase inhibitors (everolimus, RAD001). In this paper, we review the basis for mTOR inhibition in RCC, and discuss the results of the trials involving temsirolimus and everolimus for the treatment of this disease.
过去几年中，肾细胞癌的治疗方法发生了重大变化。目前已经开发出 5 种新的药物，改善了以前使用细胞因子治疗的效果。贝伐单抗、索拉非尼、舒尼替尼、替西罗莫司和依维莫司现在是治疗这种疾病的武器库的一部分。特别是，这是第一个证明哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂在 III 期临床试验中有效的肿瘤类型，无论是作为预后不良患者的一线治疗（替西罗莫司、CCI-779）还是酪氨酸激酶抑制剂治疗失败后的二线治疗（依维莫司、RAD001）。在本文中，我们回顾了 mTOR 抑制在肾细胞癌中的基础，并讨论了涉及替西罗莫司和依维莫司治疗这种疾病的试验结果。
